Chan, P. (2002) Developments in restenosis. Journal of the Renin-Angiotensin-Aldosterone System, 3 (3). pp. 145-149. ISSN 1470-3203. (doi:10.3317/jraas.2002.033) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:78337)
The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided. | |
Official URL: https://doi.org/10.3317/jraas.2002.033 |
Abstract
Restenosis is a major complication leading to the failure of vascular procedures, including surgery, angioplasty and stenting. Major efforts including over 100 clinical trials have been made to overcome this complication, with little success to date. Issues relating to trial rationale, design, measurement and biology are addressed in this review.
Item Type: | Article |
---|---|
DOI/Identification number: | 10.3317/jraas.2002.033 |
Uncontrolled keywords: | Angiotensin, Clinical trials, Restenosis, Vascular smooth muscle, angiopeptin, angiotensin 2 receptor antagonist, anticoagulant agent, cilazapril, dipeptidyl carboxypeptidase inhibitor, heparin, mevinolin, quinapril, rapamycin, somatostatin derivative, tranilast, valsartan, angioplasty, anticoagulation, blood vessel injury, brachytherapy, clinical trial, controlled clinical trial, controlled study, coronary artery disease, coronary stent, drug effect, drug efficacy, drug mechanism, gene therapy, human, hyperplasia, nonhuman, pathophysiology, regulatory mechanism, renin angiotensin aldosterone system, restenosis, review, vascular surgery, vasoconstriction |
Divisions: | Divisions > Division of Natural Sciences > Kent and Medway Medical School |
Depositing User: | Philip Chan |
Date Deposited: | 07 Nov 2019 15:16 UTC |
Last Modified: | 05 Nov 2024 12:42 UTC |
Resource URI: | https://kar.kent.ac.uk/id/eprint/78337 (The current URI for this page, for reference purposes) |
- Export to:
- RefWorks
- EPrints3 XML
- BibTeX
- CSV
- Depositors only (login required):